

# FIA8600

**Quantitative Immunoassay Analyzer** 







## **Clinical Solutions**

1. Clinical solutions to fever/inflammation

| Test Items Recommended                   | Applications   |
|--|--|
| CRP or PCT combined with                 | CRP: Used for conventional inflammation  |
| clinical signs and routine<br>blood test | PCT: Identification and diagnosis of bacterial infection, guiding the application of antibiotics |

#### 2. Clinical solutions to the diagnosis of diabetes and the evaluation of its complications

| Test Items Recommended | Clinical applications   |
|------------------------|---|
| HbA1c                  | <ul> <li>The best indicator to monitor The control of blood glucose of The diabetics<br/>Suggestions: Test once/3 months at the beginning<br/>Test once/3-6 months after meeting treatment targets</li> </ul> |
| mAlb                   | <ul> <li>Early indicator for diabetic nephropathy<br/>Suggestions: Test mAlb every year for type II diabetics<br/>Test mAlb every year for 5 years for type I diabetics (ADA Standard)</li> </ul>             |
| hs-CRP                 | The risk evaluation of cardiovascular diseases  |





# Optimized solution to acute and chronic diseases

#### + Instant testing



- 2-15 Minutes/test
- 5 Seconds/test for multiple samples

#### + Optimized operation



- One-step test
- Auto-recognition of test items
- Optional barcode scanner

### + User-friendly Design



- 7 Inch touch screen
- RFID card calibration
- Optional lithium battery

#### 3. Clinical solutions to the diagnosis and risk evaluation of cardiovascular diseases

| Patients                                | Test Items Recommended | Clinical Applications  |
|---|------------------------|--|
| Hypertensive<br>Patients                | hs-CRP                 | Risk classification of cardiovascular disease  |
|   |                        | Early evaluation of hypertensive nephropathy   |
|   | mAlb                   | <ul> <li>Risk evaluation of cardiovascular for adults with hypertension or<br/>asymptomatic diabetes</li> </ul>  |
| Patients with coronary<br>heart disease |                        | Risk classification of cardiovascular disease  |
|   | hs-CRP                 | <ul> <li>Prediction of coronary heart disease</li> </ul>   |
|   |                        | • Screening of patients with cardiovascular disease  |
|   | cTnl                   | Identification of the reasons for chest pain   |
|   |                        | <ul> <li>Risk classification and evaluation of prognosis of ACS</li> </ul>   |
|   |                        | Evaluation of infarct size   |
|   |                        | • Evaluation of the curative effect for thrombolytic therapy   |
|   | HbA1c                  | Screening of early impaired glucose metabolism for coronary artery disease patients  |
|   |                        | <ul> <li>ClSuggestions:</li> <li>Set HbA1c=5.7% as the cut-off value for patients in cardiology dept.,</li> <li>if HbA1c&gt;=5.7%, OGTT test should be done</li> </ul> |
| Patients with acute<br>heart failure    | NT-proBNP              | Identification of cardiogenic and pulmonary dyspnea  |
|   |                        | • Estimate the severity of heart failure   |
|   |                        | Evaluate the prognosis of heart failure  |
|   |                        | Guide and monitor the curative effect of heart failure   |

#### 4. Clinical solutions to the daily monitoring of pregnant women

| Test Items Recommended | Clinical Applications  |
|------------------------|--|
| HCG+β                  | <ul> <li>Diagnosis of early pregnancy and monitoring of early embryogenesis</li> <li>Evaluation of abnormal pregnancy and placental function</li> <li>Prenatal screening of Down's syndrome</li> </ul> |
| HbA1c                  | Monitor blood glucose during gestation period  |
| D-Dimer                | Monitor the function of coagulation system   |
| mAlb                   | Monitor the hypertensive renal injury caused by gestation, continuous abnormity of<br>mAlb indicates high risk of eclampsia during late gestation  |

# **Simple Operation**

#### **Inside Mode**







1.Add sample

2.Insert test kit

3.Click 'Measure' icon



4. Results printed automatically

#### **Outside Mode**







1.Add sample

2. Manually timing

3.Insert test kit





4.Click 'Measure' icon

5. Results printed automatically

# **FIA8600 Test Items**

| Cat.#   | Test Item              | Disease  | Measuring<br>Range                                      | Sample                     | Cut-off<br>Value                     | Reaction<br>Time | Qualifi           | ication      |
|---------|------------------------|--|---|----------------------------|--------------------------------------|------------------|-------------------|--------------|
| CG 3001 | cTnI                   | Myocardial infarction  | 0.50-50.00ng/ml   | S/P/WB                     | 0.50ng/ml                            | 15min            | C€                | CFDA         |
| CG 3002 | NT-proBNP              | Heart failure  | 100-35000pg/ml  | S/P/WB                     | 300pg/ml                             | 15min            | C€                | CFDA         |
| CG 3003 | hs-CRP+CRP             | Cardiovascular<br>inflammatory<br>diseases/<br>inflammatory<br>disorders                       | 0.5-200.0mg/L   | S/P/WB/<br>Fingertip Blood | 10.0mg/L<br>I 3.0mg/L                | 90s              | C€                | CFDA         |
| CG 3004 | NT-proBNP<br>/cTnI     | Heart failure/<br>acute coronary<br>syndrome   | 100-12000pg/ml<br>0.50-50.00ng/ml                       | S/P/WB                     | 300pg/ml<br>0.50ng/ml                | 18min            | C€                | CFDA         |
| CG 3005 | CK-MB<br>/cTnl<br>/Myo | Myocardial injury  | 2.50-80.00ng/ml<br>0.50-50.00ng/ml<br>30.00-1000.00ng/m | S/P/WB                     | 5.00ng/ml<br>0.50ng/ml<br>70.0ng/ml  | 15min            | C€                | CFDA         |
| CG 3006 | D-Dimer                | Venous<br>thromboembolism/<br>pulmonary embolism   | 0.10-10.00mg/L  | S/P/WB                     | 0.50mg/L                             | 7min             | C€                | CFDA         |
| CG 3007 | PCT                    | Sepsis/<br>septic shock  | 0.10-50.00ng/ml   | S/P/WB                     | 0.10ng/ml                            | 15min            | C€                | CFDA         |
| CG 3008 | CysC                   | Early diagnosis of<br>kidney disease/<br>detection of kidney<br>damage for<br>surgery patients | 0.50-10.00mg/L  | S/P/WB                     | 0.51-1.09<br>mg/L                    | 3min             | C€                | CFDA         |
| CG 3009 | mAlb                   | Early diagnosis<br>and evaluation<br>of diabetic<br>nephropathy                                | 10.0-200.0mg/L  | Urine                      | 20.0mg/L                             | 3min             | C€                | CFDA         |
| CG 3010 | NGAL                   | The best indicator of early renal injury   | 50.0-5000.0ng/ml  | S/Urine                    | Serum:200.0ng/ml<br>Urine:100.0ng/ml | 3min             | C€                | CFDA         |
| CG 3011 | β <sub>2</sub> -MG     | Kidney damage for<br>diabetic<br>& hypertensive<br>patients                                    | 0.50-20.00mg/L  | S/P/WB                     | 0.80-3.00<br>mg/L                    | 3min             | C€                | CFDA         |
| CG 3012 | CK-MB<br>/cTnI         | Myocardial injury  | 2.50-80.00ng/ml<br>0.50-50.00ng/ml                      | S/P/WB                     | 5.00ng/ml<br>0.50ng/ml               | 15min            | C€                |              |
| CG 3013 | HCG+β                  | Pregnancy early test   | 5.0-100000.0mlU/ml                                      | S/P                        | 5.10mlU/ml                           | 10min            | C€                | CFDA         |
| CG 3017 | HbA1c                  | Diabetes mellitus  | 2.00%-14.00%  | WB                         | 3.80%-5.80%                          | 3min             | <b>C€</b><br>NGSP | CFDA<br>IFCC |
| CG 3018 | CK-MB                  | Myocardial injury  | 2.50-80.00ng/ml   | S/P/WB                     | 5.00ng/ml                            | 15min            | C€                |              |
| CG 3024 | TSH                    | Thyroid diseases   | 0.10-50.00μlU/ml  | S/P                        | 0.27-4.20μIU/ml                      | 15min            | C€                |              |
| CG 3047 | H. Pylori              | H. Pylori infection  | 5-200ng/ml  | Stool                      | 100μL                                | 10min            | C€                |              |
| CG 3042 | FOB                    | Gastrointestinal<br>diseases   | 100-2000ng/ml   | Stool                      | 100μL                                | 10min            | C€                |              |

# **Exclusive distributor**



Add: Zohour District, Zagazig 14512, Egypt.

Tel efax: 0552329695

Mob: 01220108221 - 01024025659 - 01557468221

E-mail: support@guda-tek.com Website: www.guda-tek.com